Highline Wealth Partners
GSK icon

Highline Wealth Partners’s GSK GSK Stock Holding History

Highline Wealth Partners’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$28.6K Buy
594
+80
+16% +$4.08K 0.01% 360
2026
Q2 		$26.9K Sell
514
-11
-2% -$582 0.01% 338
2026
Q1 		$29K Hold
525
– – 0.01% 239
2025
Q4 		$25.7K Hold
525
– – 0.01% 215
2025
Q3 		$22.7K Buy
525
+27
+5% +$1.06K 0.01% 253
2025
Q2 		$19.1K Buy
498
+23
+5% +$879 0.01% 232
2025
Q1 		$18.4K Buy
475
+428
+911% +$15.7K 0.01% 216
2024
Q4 		$1.59K Buy
47
+7
+18% +$252 ﹤0.01% 481
2024
Q3 		$1.64K Sell
40
-54
-57% -$2.21K ﹤0.01% 468
2024
Q2 		$3.62K Buy
+94
New +$3.95K ﹤0.01% 317
2023
Q4 		– Sell
-20
Closed -$718 – 420
2023
Q3 		$725 Buy
+20
New +$710 ﹤0.01% 332

Other funds holding GSK

Mondrian Investment Partners
Mondrian Investment Partners London, United Kingdom $5.39B AUM 14.53% 1-Year Est. Return
Equity Investment Corp
Equity Investment Corp Atlanta, Georgia $5.3B AUM 8.71% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Miller Howard Investments
Miller Howard Investments Kingston, New York $3.72B AUM 18.2% 1-Year Est. Return
BI Asset Management Fondsmaeglerselskab
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $13.1B AUM 35.37% 1-Year Est. Return
Douglas Lane & Associates
Douglas Lane & Associates New York $7.46B AUM 24.36% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
Welch & Forbes
Welch & Forbes Boston, Massachusetts $8.34B AUM 13.98% 1-Year Est. Return
ABC Arbitrage
ABC Arbitrage Paris, France $1.02B AUM 30.46% 1-Year Est. Return
Foster Victor Wealth Advisors
Foster Victor Wealth Advisors Greenville, South Carolina $2.02B AUM 20.94% 1-Year Est. Return

Highline Wealth Partners's GSK Position: Q3 2026 in Review

Highline Wealth Partners increased its GSK (GSK) stake by 16% in Q3 2026, buying an estimated $4.08K and bringing the position to 594 shares worth $28.6K. The position accounts for 0.01% of the portfolio, ranked #360.

Highline Wealth Partners first reported a position in GSK in Q3 2023 and has held it in 11 quarters since. The position peaked at $29K in Q1 2026. 490 funds tracked by Wall St. Rank hold GSK as of Q3 2026.

  • Highline Wealth Partners held 594 shares of GSK worth $28.6K as of Q3 2026.
  • Highline Wealth Partners bought 80 GSK shares in Q3 2026, an estimated $4.08K.
  • GSK made up 0.01% of Highline Wealth Partners's portfolio in Q3 2026, its #360 holding.
  • Highline Wealth Partners first reported a position in GSK in Q3 2023 and has held it in 11 quarters since.
  • Highline Wealth Partners's GSK position peaked at $29K in Q1 2026.
  • 490 funds tracked by Wall St. Rank held GSK as of Q3 2026.

Based on Highline Wealth Partners's 13F filing for Q3 2026, filed 19 Oct 2026.